52 results about "Immunoresponse" patented technology

The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant PIK3CA-targeted TCRs that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The presently disclosed mutant PIK3CA peptide-specific TCRs have enhanced immune-activating properties, including anti-tumor activity.

The invention discloses a polyclonal antibody targeting a human CPNE7 variable splicing isomer and application of the polyclonal antibody, and belongs to the technical field of biological medicine. The antigen epitope 'KYKQKRRSYKN' (SEQ ID NO.1) capable of being targeted by the polyclonal antibody provided by the invention is positioned in a common conserved region of all main isomers of CPNE7, and a variable splicing region is not involved. The titer of the obtained antibody serum is as high as 1: 32,000, which indicates that the antibody has extremely high immunoreactivity and sensitivity and can be used for detecting trace proteins. The antibody disclosed by the invention can be used for effectively identifying GST-CPNE7 fusion protein expressed by a prokaryotic system and CPNE7-FL and CPNE7-S protein overexpressed in an eukaryotic system (A549 cells), and the applicability of the antibody in various experimental systems is proved. Therefore, the blank in the prior art can be filled, and a core tool is provided for research of the CPNE7 in the fields of tumor biology, diagnosis and treatment.

To provide a protein adsorption inhibitor that can suppress the adsorption of proteins to surfaces such as immunoreaction vessels and measuring instruments to a high degree, while also reducing variability between measurements. [Solution] Formula (1): Z-{O-[(PO) a (EO) b ]-(AO) c -H]} x A protein adsorption inhibitor comprising an alkylene oxide derivative represented by (the definition of the symbols in the formula is as described in the specification), wherein the cloud point of a 1% by mass aqueous solution of the alkylene oxide derivative is 0°C or higher and 30°C or lower.

This application relates to the field of tumor metabolic biomarker detection technology, and discloses a method for detecting glucose metabolism biomarkers in esophageal cancer based on VAV2-related molecular characteristics. The method includes: performing immunohistochemical staining on esophageal cancer tissue samples to obtain VAV2, EIF3F, MTA1, and HIF-1α protein expression sections; scoring the immunoreaction of each section; calculating a comprehensive glucose metabolism phenotype score based on the molecular hierarchy of the VAV2-EIF3F-MTA1 / HIF-1α glucose metabolism regulatory pathway; and classifying the samples into high-glycolytic, moderate-glycolytic, and low-glycolytic types according to the comprehensive score. This application improves the accuracy and stability of glucose metabolism phenotype discrimination in esophageal cancer.

The present application relates to a kind of based on chemotactic factor CXCL12 mutant modification double specific fusion protein and its application as immune checkpoint molecule targeted degradation platform in tumor immunotherapy, belong to biological medicine field.The specific problem of the present application is how to effectively enhance the effect of tumor immunotherapy, especially solve the problem of immune escape phenomenon in tumor microenvironment in traditional immunotherapy.To this end, the present application proposes a new KineTAC targeted degradation platform, specifically designs a new chemotactic factor CXCL12 and target protein binding polypeptide (such as anti-PD-1 / PD-L1 monoclonal antibody, anti-LAG-3 monoclonal antibody, etc.) Fusion expression protein molecule, enhance its binding affinity with receptor CXCR4 and CXCR7, and avoid stimulating tumor cell growth proliferation.The fusion protein can target and degrade the immunosuppressive molecules on the surface of tumor cells and immune cells, thereby enhancing the immune response of immune cells and improving the anti-tumor effect.

The invention discloses a preparation method and application of a PSA-ACT compound recombinant protein. The preparation method comprises the following steps: obtaining gene segments of recombinant PSA and ACT proteins; respectively connecting the gene segments to starting vectors to form corresponding connectors; carrying out conversion and screening operation on the linker to obtain a corresponding recombinant plasmid; carrying out transformation, transfection, induction and fermentation broth separation and purification operation on the recombinant plasmid to obtain recombinant PSA and ACT proteins; then activating PSA recombinant protein by using metalloproteinase, and then mixing ACT with the activated PSA to obtain a mixture containing the PSA, ACT and a PSA-ACT compound; and finally, purifying by using an ion exchange chromatography technology and a hydrophobic chromatography technology in sequence to obtain the high-purity and high-activity PSA-ACT compound. According to the method, the spontaneous reaction of ACT and activated PSA is utilized, other chemical cross-linking agents are not needed, the cost can be reduced, and the recombinant protein can be produced on a large scale; the PSA-ACT recombinant protein prepared by the method disclosed by the invention has very strong immunoreactivity.

This invention relates to an immunoassay kit and its detection system. The kit includes reagent 1 and reagent 2. The method of using the kit includes the following steps: adding a test sample containing the target molecule to containers 1 and 2 respectively; then adding an α dose of reagent 1 and reagent 2 to container 1 and a β dose of reagent 1 and reagent 2 to container 2 to perform two parallel immunoassays on the test sample; wherein the ratio of the sum of the contents of the first antibody (or antigen) and the second antibody (or antigen) in the reagents added to container 1 to the content of the target molecule is different from the ratio of the sum of the contents of the first antibody (or antigen) and the second antibody (or antigen) in the reagents added to container 2 to the content of the target molecule. The method of using the kit of this invention can directly measure up to 10 6 High sample concentrations at the ng / ml level.

The present invention provides an in vitro method for producing an immunoreactive substance against human cancer cells infected with an HPV16-related virus, the method comprising the step of expressing at least a partial nucleic acid sequence encoding an immunoreactive substance obtained from immune cells stimulated with a complex (stimulatory complex) comprising a human leukocyte antigen (HLA) and a stimulatory peptide, wherein the stimulatory peptide (i) comprises an amino acid sequence selected from SEQ ID NO: 1 and SEQ ID NO: 2, wherein the HLA is derived from the HLA supertype HLA-A01, (ii) comprises the amino acid sequence of SEQ ID NO: 11, wherein the HLA is derived from the HLA supertype HLA-A02, or (iii) comprises an amino acid sequence selected from SEQ ID NOs: 34 to 37, wherein the HLA is derived from the HLA supertype HLA-A03. (iv) the HLA is derived from HLA supertype HLA-A24; (v) the HLA is derived from HLA supertype HLA-B07; or (vi) the HLA is derived from HLA supertype HLA-B15; and an HPV16-derived peptide consisting of the same amino acid sequence as the stimulatory peptide has been verified to be presented by human HPV16-positive cancer cells, as well as methods and uses related thereto.

The invention belongs to the field of polymer chemistry and biomedical engineering, and discloses a construction method and application of a biomimetic membrane coated drug-loaded nano system. According to the system disclosed by the invention, small-molecule traditional Chinese medicine (sinomenine) is loaded in mesopores, and homologous cell membranes wrap drug-loaded nanoparticles to obtain a final nano-drug system which can effectively and passively target nasopharyngeal carcinoma cells. The sinomenine can cooperate with photothermal therapy to jointly induce mitochondrial injury, promote cell apoptosis and cause ICD immunoreaction, the sinomenine inhibits PD-L1 expression to relieve immunosuppression of T cells, meanwhile, infiltration of cytotoxic T cells in tumor sites is increased, distant metastasis of nasopharyngeal carcinoma can be inhibited by inhibiting MMPs and PD-L1, and the nasopharyngeal carcinoma can be inhibited by inhibiting MMPs and PD-L1. Therefore, the effects of enhancing nasopharynx cancer immunotherapy and inhibiting metastasis are achieved.

The application discloses a PSAP-3 protein fragment and application thereof in human echinococcosis. The polypeptide comprises an amino acid sequence as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4. The application further discloses a recombinant protein or a mutation thereof, wherein the recombinant protein comprises an amino acid sequence as shown in SEQ ID NO:5, and the amino acid sequence of the mutation has at least 80% identity with the amino acid sequence of the recombinant protein. The immunoreaction rate of the PSAP-3 recombinant protein of the application is 100%, the echinococcosis can be effectively detected, the positive detection rate is 96%, the negative detection rate is 90%, and the positive patient that cannot be detected by Egr can be detected.

The application belongs to the technical field of disease detection, and particularly relates to application of triphenylmethane compounds in detection of Alzheimer's disease. The application is accidentally discovered that triphenylmethane compounds, especially crystal violet, can be inserted into misfolded beta-sheets of A beta oligomers, so as to cause change of spectrum. Macroscopically, oxidation and discoloration are caused, so that the triphenylmethane compounds can be used for monitoring and early screening of Alzheimer's disease patients. Compared with antigen-antibody preparation of antigen-antibody immunoreaction products, the product in the application has the defects of complicated antigen-antibody preparation and high cost, and the product in the application has low cost. Meanwhile, the main component of the application is a chemical reagent, has good stability, does not need refrigeration storage condition, is convenient to transport, and is convenient to use. Meanwhile, the technical scheme of the application effectively avoids the cleaning process of enzyme-labeled plates and chemiluminescence experiments, and does not need special equipment, so that the basic medical institutions can use the application, and therefore the application has good practical application value and application prospect.

The application discloses a high-recognition and low-scattering quantum dot tubular assembly structure immunochromatography probe and a preparation method and application thereof, and first prepares a nickel-hydrazine complex nanorod, performs etching to obtain a one-dimensional hollow tubular silicon dioxide nanotube, performs mercapto-modification, constructs an oil-soluble tubular assembly through multi-layer assembly of quantum dots, transfers the assembly to an aqueous solvent through an efficient alkylsilane phase transfer strategy, deposits a thin and dense silicon oxide layer on the surface of the assembly to protect the assembly, and simultaneously performs carboxylation and coupling of a novel coronavirus antigen N protein antibody based on the silicon oxide layer to obtain a fluorescent probe. The one-dimensional hollow tubular material is used as a carrier of a signal tag, and due to double optimization of signal amplification effect and immunoreaction efficiency, the sensitivity of a lateral flow immunochromatography platform is improved, and important scientific basis is provided for early discovery, early treatment and early prevention and control of virus infection.

The application discloses a Clostridium perfringens Mbp gene and application thereof, and the nucleotide sequence of the gene is shown as SEQ ID NO. 3. The application extracts the whole genome from a virulent strain of Clostridium perfringens, designs primers to amplify the Mbp gene, and uses a prokaryotic expression method to prepare a recombinant Mbp protein. The immunoprotective effect is evaluated by using an animal experiment, and it is found for the first time that the Clostridium perfringens protein Mbp has good immunoreactivity and can significantly reduce the clinical symptoms caused by Clostridium perfringens. The Clostridium perfringens protein Mbp provided by the application has the potential to be used as a Clostridium perfringens subunit vaccine.

The invention discloses a human-derived anti-respiratory syncytial virus neutralizing antibody RS414 and application of the human-derived anti-respiratory syncytial virus neutralizing antibody RS414. The antibody RS414 is obtained by screening by using a phage surface presentation technology. The antibody specifically recognizes the respiratory syncytial virus particle antigen, aims at the F protein of the respiratory syncytial virus, has obvious enzyme-linked immunosorbent assay reaction with the respiratory syncytial virus, and has a neutralizing activity function of resisting respiratory syncytial virus infection. The antibody provided by the invention can be prepared into a specific antibody drug for preventing and treating respiratory syncytial virus infection, and can be used for clinically preventing or treating lower respiratory tract infection, especially severe lower respiratory tract infection (pneumonia and capillary bronchitis) caused by the respiratory syncytial virus.

The invention belongs to the technical field of medicines, and discloses an active targeting nano preparation for enhancing tumor immunotherapy as well as a preparation method and application of the active targeting nano preparation. A metal organic framework nanoparticle siRNAPD-L1 (at) ZIF-8 entrapped with siRNAPD-L1 is prepared through electrostatic adsorption, then the surface of the metal organic framework nanoparticle siRNAPD-L1 (at) ZIF-8 is modified with HA to prepare siRNAPD-L1 (at) HA-ZIF-8, the nano-drug realizes specific accumulation of tumor tissues through active targeting and releases Zn < 2 + > ions and siRNAPD-L1 through acid-sensitive splitting decomposition, the Zn < 2 + > ions induce pyroptosis of cells and cause immunogenic death, and the siRNAPD-L1 and the siRNAPD-L1 can be used for preparing the nano-drug. The in-vivo immune response is activated; the siRNAPD-L1 can specifically silence the PD-L1 gene in tumor cells and reduce the expression of PD-L1 protein, and the siRNAPD-L1 and the PD-L1 can synergistically play an anti-tumor role. The method is simple in preparation process, low in cost, good in stability and high in repeatability. The active targeting nano preparation disclosed by the invention is beneficial to solving the problems that siRNAPD-L1 is unstable in systemic circulation, lacks targeting and the like, so that the delivery efficiency and the anti-tumor effect of siRNAPD-L1 are improved, and the active targeting nano preparation has a relatively good development prospect in the aspect of clinical application transformation.

The invention provides a chimeric polypeptide for enhancing immunogenicity of a tumor vaccine as well as a preparation method and application of the chimeric polypeptide. The chimeric polypeptide comprises at least two connected immunological enhancement molecular fragments, and the immunological enhancement molecular fragments comprise CD40L or a functional fragment thereof, and one or more selected from a group consisting of GM-CSF or a functional fragment thereof, HMGB1 or a functional fragment thereof, HSP70 or a functional fragment thereof, FLT3L or a functional fragment thereof, and OX40L or a functional fragment thereof. According to the chimeric polypeptide provided by the invention, the mRNA has a good immunological enhancement effect in cells, antigen-specific cellular immune response can be remarkably induced, and the chimeric polypeptide serving as an immunologic adjuvant can be used for constructing an anti-tumor drug (such as an mRNA vaccine) with a better tumor treatment effect.

The invention discloses a Pt (at) Ag (at) Te-anti-PD-L1 near-infrared two-region fluorescent probe as well as a preparation method and application thereof, and belongs to the technical field of biomedical materials, the Pt (at) Ag (at) Te-anti-PD-L1 near-infrared two-region fluorescent probe takes a Pt (at) Ag (at) Te nanostructure as a core, and the surface of the Pt (at) Ag (at) Te nanostructure is modified with an anti-PD-L1 antibody; the near-infrared two-region fluorescent probe combines the functions of targeted fluorescence imaging and mild photo-thermal immune regulation, can realize efficient tumor diagnosis and precise treatment, and has the core advantages of mild photo-thermal treatment guided by fluorescence visualization, induction of anti-tumor immune response, enhancement of the treatment effect and reduction of the recurrence risk. Besides, the near-infrared two-region fluorescent probe can generate a mild heat effect under the irradiation of near-infrared light, regulate and control immune response in a tumor microenvironment, and overcome the problems of drug resistance and low response rate of immunotherapy.

The application discloses a VAT1L protein fragment and application thereof in human echinococcosis detection. The polypeptide comprises one or more of the amino acid sequences shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5. The application further discloses a recombinant protein or a mutation thereof, wherein the recombinant protein comprises an amino acid sequence shown in SEQ ID NO:6; the amino acid sequence of the mutation has at least 80% identity with the amino acid sequence of the recombinant protein and maintains the function of the recombinant protein. The immunoreaction rate of the VAT1L recombinant protein is 56%, the echinococcosis can be effectively detected, the positive detection rate is 82%, the negative detection rate is 84%, and the positive cases that cannot be detected by Egr can be detected.

An immunoassay method that is an immunologically measuring method of a target substance to be measured in a sample, the immunoassay method including performing an immunoreaction in a presence of an anti-immunoglobulin L chain lambda monoclonal antibody and an anti-immunoglobulin L chain kappa monoclonal antibody, in a presence of the anti-immunoglobulin L chain lambda monoclonal antibody, or in a presence of the anti-immunoglobulin L chain kappa monoclonal antibody. This immunoassay method enables suppression of a non-specific reaction that could not be resolved by non-specific reaction suppressing agents in the related art.

The invention belongs to the technical field of molecular detection, and provides a single molecule immunoassay kit for dual detection of NFL and NFH proteins. The kit provided by the invention comprises a solid phase carrier for fixing a specific capture antibody, a detection antibody for identifying different epitopes and marking a distinguishable signal marker, a washing liquid, a confining liquid, a calibration product and a quality control product, and the contents of NFL and NFH in a sample can be synchronously detected by combining sandwich immunoreaction with a single molecule detection technology. According to the kit provided by the invention, the detection sensitivity can reach the fg / mL level, the specificity is high, the operation is simple and convenient, traumatic cerebrospinal fluid collection is not needed, and the kit is suitable for early diagnosis, disease monitoring and curative effect evaluation of neurodegenerative diseases.

This invention belongs to the field of biomedical technology and discloses an anti-CD70 nanobody and its applications. Specifically, it discloses an anti-CD70 nanobody characterized by CD70 binding function and the ability to block the binding of the CD70-CD27 receptor ligand, and defines its specific amino acid sequence. This invention provides an anti-CD70 nanobody obtained by immunizing alpacas, exhibiting high affinity and specificity. It can be used for immunoblotting, enzyme-linked immunosorbent assay (ELISA) kits, flow cytometry detection and counting, and also for the treatment of diseases such as tumors and autoimmune diseases.

The invention discloses an expression vector, a cell and a vaccine of multivalent coronavirus recombinant protein and a preparation method of the multivalent coronavirus recombinant protein, and relates to the technical field of preparation of protein vaccines of coronavirus. A recombinant protein technical means is utilized to prepare a novel multivalent coronavirus recombinant protein, the novel multivalent coronavirus recombinant protein is prepared into a candidate vaccine, the candidate vaccine can induce an organism to generate immunoreactions aiming at different mutant strains of beta new coronavirus and alpha human coronavirus, and the generated immunoreactions are humoral immunity, cellular immunity and / or mucosal immunity. Therefore, the expression vector and the recombinant cell for expressing the novel multivalent coronavirus recombinant protein, provided by the invention, have a good application prospect. The vaccine containing the multivalent coronavirus recombinant protein has a wider coronavirus protection spectrum, the application range of the vaccine is expanded, and the vaccine has a good immunogenicity enhancing effect.

This application provides a protein adsorption inhibitor that can effectively inhibit protein adsorption onto the surfaces of immunoreaction containers, assay instruments, etc., while reducing inter-assay bias. The protein adsorption inhibitor is characterized by containing the following formula (1): Z-{O-[(PO)] a / (EO) b ]-(AO) c -H]} x (The symbols in the formula are defined as described in the specification) represent alkylene oxide derivatives, and the turbidity point of a 1% by mass aqueous solution of the alkylene oxide derivative is above 0°C and below 30°C.

The present disclosure relates to a sequential boost oncolytic viral immunotherapy and compositions for use in the same. More particularly, the disclosure relates to oncolytic viruses that significantly increase antigen-specific T cell-mediated immune responses when combined in a sequential heterologous boost treatment regimen.

The present application relates to the technical field of tumor immunotherapy, and particularly relates to a tumor neoantigen polypeptide and a method for isolating and screening the same. The amino acid sequence of the tumor neoantigen polypeptide is shown in SEQ ID NO. 1, 2, 3 or 4. The tumor neoantigen polypeptide has high affinity with HLA molecules, can induce tumor-specific T cells, and further produce an immune response targeting tumor cells. The tumor neoantigen polypeptide can be used as a target for tumor clinical treatment or diagnosis, and has good application prospect in tumor immunotherapy. The method for isolating and screening the tumor neoantigen polypeptide provided by the present application solves the problem that the existing method cannot obtain neoantigens of patients who are not treated by surgery, and provides an effective method for developing tumor neoantigen polypeptides.

The present disclosure provides a method of enhancing an immune response in a subject in need thereof, including administering an effective amount of an antigen with an immune modulator to the subject, wherein the immune modulator is a quaternary immunomodulatory nanoparticle (QIN). The present disclosure also provides the use of the QIN in the manufacture of a chimeric nanoparticle, a pharmaceutical composition and a medicament for treating a subject suffering from a cancer or virus infection.

The invention relates to the technical field of adjuvant preparation and tumor immunotherapy. The invention provides a Mn-containing nanoparticle adjuvant as well as a preparation method and application thereof. Specifically, the invention provides the Mn-containing nanoparticle adjuvant which comprises Mn < 2 + >, Mn < 3 + > and Mn < 4 + >. The preparation method of the manganese-containing particle adjuvant provided by the invention is simple, the raw materials are cheap and easy to obtain, the manganese-containing particle adjuvant has high antigen loading rate, and the innate immune response of cells can be activated by activating a cGAS-STING pathway. As a vaccine adjuvant, the vaccine adjuvant can carry antigens, effectively enhance uptake of immune cells in tumors to the antigens, and induce immunogenic death of tumor cells.

The invention discloses an immune quantitative detection device for hematologic tumor markers in the technical field of immune quantitative detection.The immune quantitative detection device comprises a shell, an immune reaction module and a detection module are arranged in the shell, the immune reaction module comprises a sample containing container, a driving piece is installed in the sample containing container and connected with a cylindrical cam, and the cylindrical cam is connected with the detection module; a sliding groove is formed in the outer side wall of the cylindrical cam, a sliding block is arranged in the sliding groove in a sliding fit mode and connected with a vertical rod, the vertical rod is sleeved with a spring, and the spring is sleeved with a drainage tube. The vertical rod is of a hollow structure, round holes communicated with the outside are formed in the middle and the bottom end of the vertical rod, the drainage tube penetrates through the bottom of the sample containing container and is fixedly connected with the sample containing container, the detection module comprises a detector, the detector is in signal connection with a controller, and the controller is in signal connection with the motor. The detection process is automatically completed by the detection device and can be completed in a short time, the detection efficiency is improved, the size is small, carrying is convenient, and detection work can be carried out anytime and anywhere.

This invention provides a wash-free, competitive immunoassay method capable of simultaneous multiplex detection. Specifically, this invention utilizes self-developed Raman microspheres (R-Sphere) with non-overlapping Raman signals to conjugate specific antibodies against the target molecule onto the Raman microspheres. The target molecule is then detected through an immunoassay. Raman microsphere-antibody conjugates that do not bind to the target molecule are adsorbed onto the container wall via carboxyl magnetic beads, thereby eliminating background signal interference. This method offers advantages such as wash-free operation, separation-free operation, ease of use, high accuracy, and the ability to simultaneously detect multiple signals.